{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:20:09Z","timestamp":1781533209104,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00277-019-03856-y","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T06:02:52Z","timestamp":1574748172000},"page":"385-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-dose pembrolizumab\u00a0induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Joycelyn P. Y.","family":"Sim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rex","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"3856_CR1","first-page":"453","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Webber SA, Chadburn A, Ferry JA (2017) Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 453\u2013462"},{"issue":"3","key":"3856_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bcmd.2014.11.009","volume":"54","author":"CY Cheung","year":"2015","unstructured":"Cheung CY, Tam S, Lam CW, Lie AK, Kwong YL (2015) Allogeneic haematopoietic stem cell transplantation for erythropoietic protoporphyria: a cautionary note. Blood Cells Mol Dis 54(3):266\u2013267. https:\/\/doi.org\/10.1016\/j.bcmd.2014.11.009","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"3856_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/leu.2013.212","volume":"28","author":"YL Kwong","year":"2014","unstructured":"Kwong YL, Pang AW, Leung AY, Chim CS, Tse E (2014) Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 28(4):865\u2013870. https:\/\/doi.org\/10.1038\/leu.2013.212","journal-title":"Leukemia"},{"issue":"23","key":"3856_CR4","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690\u20132697. https:\/\/doi.org\/10.1200\/JCO.2016.66.4482","journal-title":"J Clin Oncol"},{"issue":"21","key":"3856_CR5","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","volume":"130","author":"WR Liu","year":"2017","unstructured":"Liu WR, Shipp MA (2017) Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130(21):2265\u20132270. https:\/\/doi.org\/10.1182\/blood-2017-06-781989","journal-title":"Blood"},{"issue":"6","key":"3856_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611\u20131618. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1942","journal-title":"Clin Cancer Res"},{"issue":"19","key":"3856_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A (2017) Moskowitz CH; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"4","key":"3856_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-017-2931-z","volume":"96","author":"TS Chan","year":"2017","unstructured":"Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed\/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647\u2013651. https:\/\/doi.org\/10.1007\/s00277-017-2931-z","journal-title":"Ann Hematol"},{"issue":"7","key":"3856_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00277-017-3007-9","volume":"96","author":"YY Hwang","year":"2017","unstructured":"Hwang YY, Khong PL, Kwong YL (2017) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96(7):1219\u20131220. https:\/\/doi.org\/10.1007\/s00277-017-3007-9","journal-title":"Ann Hematol"},{"issue":"7","key":"3856_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00277-016-2651-9","volume":"95","author":"YL Kwong","year":"2016","unstructured":"Kwong YL (2016) Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol 95(7):1191\u20131192. https:\/\/doi.org\/10.1007\/s00277-016-2651-9","journal-title":"Ann Hematol"},{"issue":"18","key":"3856_CR11","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesqui\u00e8res H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471\u20132478. https:\/\/doi.org\/10.1182\/blood-2016-11-749556","journal-title":"Blood"},{"issue":"1","key":"3856_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03856-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03856-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03856-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:38:02Z","timestamp":1606264682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03856-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3856"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03856-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient gave informed consent to treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of informed consent"}}]}}